Lantern Pharma Quote - LTRN

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

3.40

Bid

3.31

Offer

3.40

Volume

76,053

3.07 Day's Range 3.41

2.79 52 Week Range 11.99

Market Cap

36.668M

Previous Close

3.42

Open

3.41

Last Trade

3.272

Last Trade Time

03:03:16

Financial Volume

US$ 243,511

VWAP

3.2019

Average Volume (3m)

57,325

Shares Outstanding

10,784,725

Dividend Yield

PE Ratio

-2.24

Earnings Per Share (EPS)

-1.48

Revenue

Net Profit

-15.96M

Lantern Pharma Inc is a clinical-stage biotechnology company. It is focused on leveraging artificial intelligence (A.I), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firm's pipeline o... Lantern Pharma Inc is a clinical-stage biotechnology company. It is focused on leveraging artificial intelligence (A.I), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firm's pipeline of development programs involves four drug candidates and an Antibody Drug Conjugate (ADC) program directed towards eight therapeutic targets. Its A.I. platform, known as RADR, includes more than 18 billion data points, and uses big data analytics and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that we believe may benefit most from our compounds. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Headquarters

Wilmington, Delaware, USA

Founded

Lantern Pharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LTRN. The last closing price for Lantern Pharma was US$3.42. Over the last year, Lantern Pharma shares have traded in a share price range of US$ 2.79 to US$ 11.99.

Lantern Pharma currently has 10,784,725 shares in issue. The market capitalisation of Lantern Pharma is US$36.88 million. Lantern Pharma has a price to earnings ratio (PE ratio) of -2.24.

Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Multiple clinical trial sites across Taiwan are actively screening patients, following successful site initiation visits. Expansion into Taiwan is particularly significant as over 50% of lung...

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)

This is the second Fast Track Designation granted to LP-184 in 2024, following the designation for Glioblastoma (GBM) announced in October 2024. Fast Track Designation for LP-184 recognizes TNBC...

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality

The Phase 1b clinical trial design presented at SNO2024 combines LP-184 (STAR-001) with spironolactone to potentially enhance therapeutic response in recurrent glioblastoma (GBM) patients...

Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Ten clinical trial sites across Japan and Taiwan are actively screening patients, with additional sites expected to also begin patient enrollment in the coming months U.S. clinical sites...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.23	7.25552050473	3.17	3.97	3.01	86208	3.34422401	CS
4	0.14	4.29447852761	3.26	4.88	3.01	79144	3.61315724	CS
12	-0.32	-8.60215053763	3.72	4.88	2.79	57325	3.46447843	CS
26	-1.36	-28.5714285714	4.76	5.1	2.79	52968	3.77625568	CS
52	-0.84	-19.8113207547	4.24	11.99	2.79	124920	6.30130508	CS
156	-4.11	-54.7270306258	7.51	11.99	2.38	67642	5.88043432	CS
260	-11.76	-77.5725593668	15.16	24.84	2.38	74546	9.47119831	CS

LTRN - Frequently Asked Questions (FAQ)

What is the current Lantern Pharma share price?

The current share price of Lantern Pharma is US$ 3.40

How many Lantern Pharma shares are in issue?

Lantern Pharma has 10,784,725 shares in issue

What is the market cap of Lantern Pharma?

The market capitalisation of Lantern Pharma is USD 36.88M

What is the 1 year trading range for Lantern Pharma share price?

Lantern Pharma has traded in the range of US$ 2.79 to US$ 11.99 during the past year

What is the PE ratio of Lantern Pharma?

The price to earnings ratio of Lantern Pharma is -2.24

What is the reporting currency for Lantern Pharma?

Lantern Pharma reports financial results in USD

What is the latest annual profit for Lantern Pharma?

The latest annual profit of Lantern Pharma is USD -15.96M

What is the registered address of Lantern Pharma?

The registered address for Lantern Pharma is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

Which industry sector does Lantern Pharma operate in?

Lantern Pharma operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
WATTEnergous Corporation	US$ 1.66 (303.70%)	147.46M
NXUNXU Inc	US$ 0.9479 (289.44%)	283.29M
INTZIntrusion Inc	US$ 5.60 (159.26%)	101.64M
CYNCYNGN Inc	US$ 1.36 (116.59%)	27.18M
VINCVincerx Inc	US$ 0.3925 (102.32%)	258.7M
ABPAbpro Holdings Inc	US$ 2.3076 (-48.61%)	815.51k
TRAWTraws Pharma Inc	US$ 8.2234 (-38.72%)	769.8k
LITMSnow Lake Resources Ltd	US$ 1.185 (-25.94%)	38.83M
BITSGlobal X Blockchain and Bitcoin Stratagy ETF	US$ 66.34 (-25.01%)	7.08k
TOIIWOncology Institute Inc	US$ 0.0084 (-22.94%)	75.47k
NXUNXU Inc	US$ 0.9483 (289.61%)	283.3M
VINCVincerx Inc	US$ 0.3922 (102.16%)	258.71M
WATTEnergous Corporation	US$ 1.65 (301.26%)	147.47M
XTIAXTI Aerospace Inc	US$ 0.0401 (1.52%)	145.31M
INTZIntrusion Inc	US$ 5.5932 (158.94%)	101.64M